Aptahem on the need for more effective sepsis treatments

Biotechnology company Aptahem is developing Apta-1, a drug candidate whose purpose is to reduce the high mortality and severe tissue damage that can occur in sepsis.

BioStock contacted Luiza Jedlina, Chief Scientific Officer and co-founder of Aptahem, to talk about the need for better treatment options than antibiotics. Sepsis is a potentially life-threatening inflammatory.